A novel genomic inversion in Wiskott-Aldrich–associated autoinflammation
2016; Elsevier BV; Volume: 138; Issue: 2 Linguagem: Inglês
10.1016/j.jaci.2016.03.007
ISSN1097-6825
AutoresImmacolata Brigida, Samantha Scaramuzza, Dejan Lazarević, Davide Cittaro, Francesca Ferrua, Lorena Leonardelli, Maria Alessio, Ornella Forma, Chiara Lanzani, Gianluca Viarengo, Fabio Ciceri, Momcilo Jankovic, Fernando Pesce, Alessandro Aiuti, Maria Pia Cicalese,
Tópico(s)Wound Healing and Treatments
ResumoWiskott-Aldrich syndrome (WAS) is an X-linked disorder characterized by thrombocytopenia, eczema, and immunodeficiency. Up to 70% of patients with WAS present with at least 1 autoimmune or autoinflammatory episode, and many of them suffer from recurrent or multiple events.1Dupuis-Girod S. Medioni J. Haddad E. Quartier P. Cavazzana-Calvo M. Le Deist F. et al.Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients.Pediatrics. 2003; 111: e622-e627Crossref PubMed Scopus (268) Google Scholar, 2Chen N. Zhang Z.Y. Liu D.W. Liu W. Tang X.M. Zhao X.D. The clinical features of autoimmunity in 53 patients with Wiskott-Aldrich syndrome in China: a single-center study.Eur J Pediatr. 2015; 174: 1311-1318Crossref PubMed Scopus (13) Google Scholar, 3Imai K. Morio T. Zhu Y. Jin Y. Itoh S. Kajiwara M. et al.Clinical course of patients with WASP gene mutations.Blood. 2004; 103: 456-464Crossref PubMed Scopus (304) Google Scholar IL-1 new-generation blockers have been used in patients exhibiting clinical symptoms compatible with an autoinflammatory condition,4Geusau A. Mothes-Luksch N. Nahavandi H. Pickl W.F. Wise C.A. Pourpak Z. et al.Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment.JAMA Dermatol. 2013; 149: 209-215Crossref PubMed Scopus (59) Google Scholar but have not been reported in WAS. Here, we describe a patient with WAS with a peculiar large genomic inversion presenting with multiple manifestations of immune dysregulation, in whom autoinflammatory manifestations improved after the use of anakinra (IL-1 receptor antagonist, Kineret). A 11.6-year-old boy was referred to our center for suspected immunodeficiency. The patient presented with a history of microthrombocytopenia since birth and eczema in the first years of life, suggestive of WAS. Analysis of WAS protein (WASp) expression was reported abnormal, but Sanger sequencing on DNA did not reveal mutations. From 1.5 years of age he underwent recurrent episodes of postinfectious vasculitis of the lower limbs and arthritis. At 7.5 years, he presented with a bilateral pneumonia that triggered Schonlein-Henoch purpura with fever and arthritis, managed with oral steroids. Subsequently, a nephritic-nephrotic syndrome was treated with antihypertensive treatment and high-dose corticosteroids (CCS), with partial response. Cyclosporin A (CyA) and CCS led to remission of renal disease, which relapsed after CyA was stopped. Intravenous high-dose CCS and anti-CD20 mAb did not lead to substantial improvement. CyA and low-dose prednisone were restarted with partial benefit. However, the patient experienced varicella zoster reactivation on his half-right-face, with sequelae to the right eye (anterior and posterior uveitis with acute retinitis) requiring a vitrectomy, and severe impairment of visual function. An anterior uveitis at the left eye was treated with steroids. At the age of 9.8 years, he developed clinical and histological features of pancolitic Crohn disease, managed with an increase in CCS, as well as arthritis and histologically confirmed vasculitis and eventually pyoderma gangrenosum (PG) on the hips, buttocks, and upper and lower limbs. Crohn disease was not responsive to infliximab, thalidomide, cyclophosphamide, or high-dose intravenous steroids, while adalimumab (Humira) resulted in an initial benefit (see Table E1 in this article's Online Repository at www.jacionline.org). The patient presented with fistulas and perianal abscesses when he was 10.7 years old and he underwent several fistulectomies and removal of granulation tissue in the perianal area by "cone-like technique." For the poor control of the enterocolitis, a subtotal colectomy with terminal ileostomy was performed at age 11 years. When the patient was referred to our center, he was on adalimumab and low-dose CCS with a good control of bowel disease, but still showed severe manifestations of PG on the upper limbs and in the perianal area (Fig 1, A; see Table E2 in this article's Online Repository at www.jacionline.org). His parents signed informed consent for research investigations (protocol Tiget06). Because of the strong suspicion of WAS, whole-genome sequencing was performed and an inversion of 6kb spanning from the promoter to the intronic region between exons 7 and 8 was detected (see Fig E1 in this article's Online Repository at www.jacionline.org). Specific primers in this region identified the precise breaking points (see Tables E3 and E4 in this article's Online Repository at www.jacionline.org; Fig 2, B). The rearranged allele was present in the patient and his mother, whereas the patient's aunt was unaffected (data not shown and Fig 2, A-C). RNA analyses showed an aberrant transcript produced from the inverted region (Fig 2, D). WASp expression, analyzed by flow cytometry (see Fig E2, A, in this article's Online Repository at www.jacionline.org), was deeply reduced in peripheral blood T-, B-, and natural killer lymphocytes and monocytes (data not shown) while it was undetectable by Western blot performed with an antibody recognizing the N-terminal portion of WASp including exons 7 and 8 (Fig E2, B). WASp expression was restored in the patient's T-cell line transduced with a lentiviral vector expressing WASp under the control of the autologous 1.6-kb long promoter5Scaramuzza S. Biasco L. Ripamonti A. Castiello M.C. Loperfido M. Draghici E. et al.Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome.Mol Ther. 2013; 21: 175-184Abstract Full Text Full Text PDF PubMed Scopus (67) Google Scholar (Fig E2, C). The start of low-dose methotrexate (Reumaflex) and the increase in prednisone led to a moderate improvement in the PG after 3 months (Fig 1, B), but shortly after the patient underwent a reactivation of vasculitis and arthritis with systemic inflammation that was not controlled by multiple immunosuppressive and anti-inflammatory drugs. On the basis of the reported efficacy of IL-1 blockers in the treatment of autoinflammatory manifestations and of PG,4Geusau A. Mothes-Luksch N. Nahavandi H. Pickl W.F. Wise C.A. Pourpak Z. et al.Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment.JAMA Dermatol. 2013; 149: 209-215Crossref PubMed Scopus (59) Google Scholar anakinra was started as an off-label drug titrating the dose from 1 up to 3 mg/kg/day. This led to a resolution of vasculitis and arthritis and to a decrease in the inflammation indexes within few days (Fig 1, D) with dramatic improvement in the PG skin lesions during the following 5 months (Fig 1, C). The patient was enrolled in a gene therapy trial based on autologous gene-corrected hematopoietic stem cells (clinicaltrials.gov #NCT01515462), mobilized with G-CSF and plerixafor. Treatment with anakinra was discontinued 48 hours before mobilization, but was soon restarted because of the increase in white blood cells and inflammation indexes with exacerbation of skin lesions, arthralgia, and hematuria, and led again to a rapid laboratory and clinical remission (data not shown). Notably, the use of anakinra allowed a successful mobilization with G-CSF without the occurrence of other autoinflammatory manifestations. To our knowledge, this is the first reported case of use of IL-1R blocker in a patient with WAS, with clinical benefit. This case is very emblematic for several reasons. Whole-genome sequencing complemented by specific breakpoint sequencing allowed the identification of the inversion with intact exon sequences, elucidating the previous normal genetic analysis. Complex genomic rearrangements involving inversions are generally noncanonical gene conversion events6Chen J.M. Chuzhanova N. Stenson P.D. Férec C. Cooper D.N. Intrachromosomal serial replication slippage in trans gives rise to diverse genomic rearrangements involving inversions.Hum Mutat. 2005; 26: 362-373Crossref PubMed Scopus (58) Google Scholar and could have occurred in an ancestor allele in the family through a de novo mutation occurring in the mother. Autoimmune and autoinflammatory manifestations in patients with WAS typically present early in life, are often refractory to therapy, and are associated with a worse clinical prognosis and an increased risk of developing a malignancy.3Imai K. Morio T. Zhu Y. Jin Y. Itoh S. Kajiwara M. et al.Clinical course of patients with WASP gene mutations.Blood. 2004; 103: 456-464Crossref PubMed Scopus (304) Google Scholar, 7Moratto D. Giliani S. Bonfim C. Mazzolari E. Fischer A. Ochs H.D. et al.Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study.Blood. 2011; 118: 1675-1684Crossref PubMed Scopus (232) Google Scholar Our patient's autoinflammatory manifestations were resistant to several immunosuppressive drugs and the use of CyA was associated with a severe viral complication. Anakinra dramatically improved PG, vasculitis, and arthritis, showed a good safety profile, and allowed stabilization of the patient for definitive treatment. The response to anakinra suggests that the dysregulation of the innate immune system is involved in the genesis of autoinflammatory manifestations in patients with WAS and shows that IL-1 may serve in selected cases as a target for therapy, avoiding the use of other classes of immunosuppressors that can increase the risk for severe infections. It has been hypothesized that defects in chemotaxis and podosomes formation in WASp-deficient cells may favor the onset of autoinflammatory manifestations. In addition, a recent study in a patient with aggressive PG showed a critical role for proline-serine-threonine phosphatase interacting protein 1, which is involved in cytoskeletal regulatory functions through interaction with WASp, in the Pyogenic Arthritis, Pyoderma gangrenosum, and Acne syndrome.8Starnes T.W. Bennin D.A. Bing X. Eickhoff J.C. Grahf D.C. Bellak J.M. et al.The F-BAR protein PSTPIP1 controls extracellular matrix degradation and filopodia formation in macrophages.Blood. 2014; 123: 2703-2714Crossref PubMed Scopus (63) Google Scholar A greater understanding of the role of WASp in inflammation and of potential pathways that may be targeted therapeutically to modulate immunity in WAS is desirable to improve the management of the affected patients while waiting for definitive treatment by stem cell transplantation or gene therapy. Fig E2WASp expression. A, Flow cytometry characterization of WASp expression in patient and HC lymphocytes. Percentage of WASp+ cells is reported on histograms. Detection of WASp was performed after permeabilization (Cytofix/Cytoperm kit; BD Biosciences, San Jose, Calif) by a noncommercial rabbit polyclonal antibody ("EFOB," generated against a WASp peptide), kindly provided by GSK. Gray line: negative control. B, Western blot performed on untransformed T-cell line generated in vitro from patient and his parents. Antibody for detection: polyclonal H250 (BD). C, Restoration of WASp expression in a patient's T-cell line after transduction with LV. GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; HC, healthy control; LV, lentiviral vector; Pt, patient.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Table E1Summary of treatment of possible autoimmune and autoinflammatory manifestationsTreatmentResponseNephritic/nephrotic syndrome SteroidsPartial Steroids + CyARemission, then relapse when CyA stopped Steroids + anti-CD20 mAbNo Steroids + CyAPartial; infectious complicationsCrohn disease Steroids + CyANo Steroids + CyA + IVIGNo Steroids + CyA + infliximabPartial, then relapse Steroids + CyA + talidomideNo Steroids + cyclophosphamideNo Steroids + adalimumabYesPG Steroids + dapsone + adalimumabNo Steroids + dapsone + adalimumab + MTXPartial Steroids + dapsone + anakinraYesArthritis and vasculitis Steroids + CyARemission, then relapse Steroids + CyA + infliximabNo Steroids + dapsone + adalimumab + MTXNo Steroids + dapsone + anakinraYesIVIG, Intravenous immunoglobulin; MTX, methotrexate. Open table in a new tab Table E2Clinical data and significant laboratory findings at WAS diagnosisAge of onset/diagnosis of diseaseNeonatal/11.6 yGenetic analyses (whole-genome sequencing)inv(X)g.5721-11840Clinical manifestationsMicrothrombocytopeniaMild eczema, severe infections, arthritis, vasculitisMultiple Henoch-Schonlein purpura episodesNephritic-nephrotic syndrome, panuveitisSteroid-resistant Chron enterocolitisPerianal fistulas and abscessesPGZhu score5AE1Zhu Q. Watanabe C. Liu T. Hollenbaugh D. Blaese R.M. Kanner S.B. et al.Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype.Blood. 1997; 90: 2680-2689PubMed Google ScholarWBC (×109/L) (normal value, 4.8-10.8 × 109/L)14.4Neutrophils (×109/L) (normal value, 1.8-7.7 × 109/L)12.7Lymphocytes (×109/L)1Platelets range (×109/L)20-40MPV (fl) (normal value, 9.1-12.5)8CD3+ (cells/μL) (normal value, 1000-2100)E2Comans-Bitter W.M. de Groot R. van den Beemd R. Neijens H.J. Hop W.C. Groeneveld K. et al.Immunophenotyping of blood lymphocytes in childhood: reference values for lymphocyte subpopulations.J Pediatr. 1997; 130: 388-393Abstract Full Text Full Text PDF PubMed Scopus (613) Google Scholar498CD3+CD4+ (cells/μL) (normal value, 500-1300)E2Comans-Bitter W.M. de Groot R. van den Beemd R. Neijens H.J. Hop W.C. Groeneveld K. et al.Immunophenotyping of blood lymphocytes in childhood: reference values for lymphocyte subpopulations.J Pediatr. 1997; 130: 388-393Abstract Full Text Full Text PDF PubMed Scopus (613) Google Scholar364CD3+CD8+ (cells/μL) (normal value, 220-950)E2Comans-Bitter W.M. de Groot R. van den Beemd R. Neijens H.J. Hop W.C. Groeneveld K. et al.Immunophenotyping of blood lymphocytes in childhood: reference values for lymphocyte subpopulations.J Pediatr. 1997; 130: 388-393Abstract Full Text Full Text PDF PubMed Scopus (613) Google Scholar91CD19+ (cells/μL) (normal value, 180-600)E2Comans-Bitter W.M. de Groot R. van den Beemd R. Neijens H.J. Hop W.C. Groeneveld K. et al.Immunophenotyping of blood lymphocytes in childhood: reference values for lymphocyte subpopulations.J Pediatr. 1997; 130: 388-393Abstract Full Text Full Text PDF PubMed Scopus (613) Google Scholar101CD16+CD56+ (cells/μL) (normal value, 170-670)E2Comans-Bitter W.M. de Groot R. van den Beemd R. Neijens H.J. Hop W.C. Groeneveld K. et al.Immunophenotyping of blood lymphocytes in childhood: reference values for lymphocyte subpopulations.J Pediatr. 1997; 130: 388-393Abstract Full Text Full Text PDF PubMed Scopus (613) Google Scholar338CD4+CD45RA+ (cells/μL) (normal value, 320-1000)E3Shearer W.T. Rosenblatt H.M. Gelman R.S. Oyomopito R. Plaeger S. Stiehm R. et al.Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study.J Allergy Clin Immunol. 2003; 112: 973-980Abstract Full Text Full Text PDF PubMed Scopus (634) Google Scholar152CD4+CD45RO+ (cells/μL) (normal value, 230-630)E3Shearer W.T. Rosenblatt H.M. Gelman R.S. Oyomopito R. Plaeger S. Stiehm R. et al.Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study.J Allergy Clin Immunol. 2003; 112: 973-980Abstract Full Text Full Text PDF PubMed Scopus (634) Google Scholar201CD8+CD45RA+ (cells/μL) (normal value, 310-900)E3Shearer W.T. Rosenblatt H.M. Gelman R.S. Oyomopito R. Plaeger S. Stiehm R. et al.Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study.J Allergy Clin Immunol. 2003; 112: 973-980Abstract Full Text Full Text PDF PubMed Scopus (634) Google Scholar159CD8+CD45RO+ (cells/μL) (normal value, 70-390)E3Shearer W.T. Rosenblatt H.M. Gelman R.S. Oyomopito R. Plaeger S. Stiehm R. et al.Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study.J Allergy Clin Immunol. 2003; 112: 973-980Abstract Full Text Full Text PDF PubMed Scopus (634) Google Scholar40Vβ repertoirePolyclonal on CD3+IgG (g/L) (normal value, 7.07-19.19)E4Burgio GR, Perinotto G, Ugazio AG. Pediatria essenziale. UTET editore. 1991.Google Scholar7.69 (on IVIG supplementation)IgA (g/L) (normal value, 0.60-2.7)E4Burgio GR, Perinotto G, Ugazio AG. Pediatria essenziale. UTET editore. 1991.Google Scholar6.68IgM (g/L) (normal value, 0.61-2.76)E4Burgio GR, Perinotto G, Ugazio AG. Pediatria essenziale. UTET editore. 1991.Google Scholar0.33Autoimmunity screening∗Including Coombs test, ANA, ENA, AMA, ASMA, anti–LKM1 antibody, anti–dS-DNA antibody, ASCA, cANCA, pANCA, ACA, and anti–β2 glicoprotein antibody.NegativeAntiplatelets antibody (indirect test)PositiveLLACNegativeACA, Anticardiolipin antibody; AMA, antimitochondrial antibody; ANA, antinuclear antibody; ASCA, anti–Saccharomyces cerevisiae antibody; ASMA, anti–smooth muscle antibody; cANCA, cytoplasmic antineutrophilic cytoplasmic antibodies; ds-DNA, double-strand DNA antibody; ENA, extractable nuclear antibodies; IVIG, intravenous immunoglobulin; LLAC, lupus-like anticoagulant; LKM1, liver kidney microsomal type 1 antibody; pANCA, protoplasmic antineutrophilic cytoplasmic antibodies; WBC, white blood cell.∗ Including Coombs test, ANA, ENA, AMA, ASMA, anti–LKM1 antibody, anti–dS-DNA antibody, ASCA, cANCA, pANCA, ACA, and anti–β2 glicoprotein antibody. Open table in a new tab Table E3Primers for the detection of DNA inversionPrimerOrientationSequencePCR cyclesAFORCTGGAGATACGCCTAGCACA94°C 3 min, 94°C 30 s, 55°C 30 s, 72°C 1 min × 40 cycles, 72°C 10 minREVTCTGAGGGCTGTAGGGTTTGBFORAAGGTGGGCACATGGGTAG94°C 3 min, 94°C 30 s, 55°C 30 s, 72°C 1 min × 40 cycles, 72°C 10 minREVTCTCAGCAGTGGTCTTTGGA Open table in a new tab Table E4Primers for amplification of cDNARegionOrientationSequencePCR cyclesEXON1-4 (279bp)FORCGAAAATGCTTGACGCTGGC94°C 3 min, 94°C 30 s, 54.6°C 30 s, 72°C 1 min × 40 cycles, 72°C 10 minREVCTCGTCCTCGTCTGCAAAGTEXON7-10 (303bp)FORACCCAGTGGATTCAAGCATGT94°C 3 min, 94°C 30 s, 54.6°C 30 s, 72°C 1 min × 40 cycles, 72°C 10 minREVGGACCAGAACGACCCTTGTTEXON2-7 (449bp)FORGTCCTACTTCATCCGCCTTTAC94°C 3 min, 94°C 30 s, 55.8°C 30 s, 72°C 1 min × 40 cycles, 72°C 10 minREVTCTTCCCTGAGCGTTTCTTATCEXON7-8 (73bp)FORGTGGATTCAAGCATGTCAGCC94°C 3 min, 94°C 30 s, 55.8°C 30 s, 72°C 1 min × 40 cycles, 72°C 10 minREVTCTGGGTCGAGGTTGTTCAC Open table in a new tab IVIG, Intravenous immunoglobulin; MTX, methotrexate. ACA, Anticardiolipin antibody; AMA, antimitochondrial antibody; ANA, antinuclear antibody; ASCA, anti–Saccharomyces cerevisiae antibody; ASMA, anti–smooth muscle antibody; cANCA, cytoplasmic antineutrophilic cytoplasmic antibodies; ds-DNA, double-strand DNA antibody; ENA, extractable nuclear antibodies; IVIG, intravenous immunoglobulin; LLAC, lupus-like anticoagulant; LKM1, liver kidney microsomal type 1 antibody; pANCA, protoplasmic antineutrophilic cytoplasmic antibodies; WBC, white blood cell. CorrectionJournal of Allergy and Clinical ImmunologyVol. 139Issue 5PreviewWith regard to the article in the August 2016 issue entitled "A novel genomic inversion in Wiskott-Aldrich–associated autoinflammation" (J Allergy Clin Immunol 2016;138:619-22.e7), the authors wish to amend the Acknowledgment section. The authors would like to thank the Italian Ministero della Salute (Programma di rete, NET-2011-02350069) and the European Commission (ERARE-3-JTC 2015 EUROCID). I.B. is supported by the Italian Ministero della Salute (GR-2011-02346985). The authors regret the omission. Full-Text PDF Open Access
Referência(s)